Cost-effectiveness of primary screening for CKD: A systematic review

American Journal of Kidney Diseases

Volumn 63, Issue 5, 2014, Pages 789-797

  Komenda, Paul ^a,b   Ferguson, Thomas W ^a,b   Macdonald, Kerry ^a   Rigatto, Claudio ^a,b   Koolage, Chris ^a,b   Sood, Manish M ^c   Tangri, Navdeep ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Seven Oaks General Hospital   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

chronic kidney disease (CKD); Cost effectiveness analysis; estimated glomerular filtration rate (eGFR); incremental cost effectiveness ratio (ICER); Index Words; proteinuria; public health screening; risk stratification

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; EMBASE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MASS SCREENING; MEDLINE; MICROALBUMINURIA; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW;

CHRONIC KIDNEY DISEASE (CKD); COST-EFFECTIVENESS ANALYSIS; ESTIMATED GLOMERULAR FILTRATION RATE (EGFR); INCREMENTAL COST-EFFECTIVENESS RATIO (ICER); PROTEINURIA; PUBLIC HEALTH SCREENING; RISK STRATIFICATION;

COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; MASS SCREENING; RENAL INSUFFICIENCY, CHRONIC; WORLD HEALTH;

EID: 84898872450     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.12.012     Document Type: Article

References (36)

1. A.S. Levey, R. Atkins, and J. Coresh et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes Kidney Int 72 3 2007 247 259
2. L.S. Dalrymple, R. Katz, and B. Kestenbaum et al. Chronic kidney disease and the risk of end-stage renal disease versus death J Gen Intern Med 26 4 2011 379 385
3. N. Tangri, L.A. Stevens, and J. Griffith et al. A predictive model for progression of chronic kidney disease to kidney failure JAMA 305 15 2011 1553 1559
4. M.P. McTaggart, C.P. Price, R.G. Pinnock, P.E. Stevens, R.G. Newall, and E.J. Lamb The diagnostic accuracy of a urine albumin-creatinine ratio point-of-care test for detection of albuminuria in primary care Am J Kidney Dis 60 5 2012 787 794
5. S.D. Grosse Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Expert Rev Pharmacoecon Outcomes Res 8 2 2008 165 178
6. World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). Updated 2012. World Health Organization Web site. http://www.who.int/choice/costs/CER-thresholds/en/index.html. Accessed December 16, 2012.
7. M.F. Drummond, and M.F. Drummond Methods for the Economic Evaluation of Health Care Programmes 3rd ed 2005 Oxford University Press Oxford, NY 379
8. K.F. Schulz, D.G. Altman, D. Moher CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials Int J Surg 9 8 2011 672 677
9. C. Boersma, R.T. Gansevoort, and P. Pechlivanoglou et al. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands Clin Ther 32 6 2010 1103 1121
10. T.J. Hoerger, J.S. Wittenborn, and J.E. Segel et al. A health policy model of CKD: 2. the cost-effectiveness of microalbuminuria screening Am J Kidney Dis 55 3 2010 463 473
11. T.J. Hoerger, J.S. Wittenborn, and J.E. Segel et al. A health policy model of CKD: 1. model construction, assumptions, and validation of health consequences Am J Kidney Dis 55 3 2010 452 462
12. R. Kessler, G. Keusch, and T.D. Szucs et al. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland Swiss Med Wkly 142 2012 w13508
13. A.J. Palmer, W.J. Valentine, and R. Chen et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA Nephrol Dial Transplant 23 4 2008 1216 1223
14. L.E. Boulware, B.G. Jaar, M.E. Tarver-Carr, F.L. Brancati, and N.R. Powe Screening for proteinuria in US adults: a cost-effectiveness analysis JAMA 290 23 2003 3101 3114
15. K. Howard, S. White, and G. Salkeld et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis Value Health 13 2 2010 196 208
16. M. Kondo, K. Yamagata, and S.L. Hoshi et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan Clin Exp Nephrol 16 2 2012 279 291
17. J.E. Siegel, A.S. Krolewski, J.H. Warram, and M.C. Weinstein Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus J Am Soc Nephrol 3 4 suppl 1 1992 S111 S119
18. B. Manns, B. Hemmelgarn, and M. Tonelli et al. Population based screening for chronic kidney disease: cost effectiveness study BMJ 341 2010 c5869
19. J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, and A.S. Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 1 2003 1 12
20. H.H. Parving, E. Hommel, and E. Mathiesen et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes Br Med J 296 6616 1988 156 160
21. M. Firmann, V. Mayor, and P.M. Vidal et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome BMC Cardiovasc Disord 8 2008 6
22. PREVEND. Prevention of renal and vascular endstage disease. Prevention of Renal and Vascular Endstage Disease Web site. http://www.prevend.org/. Accessed December 21, 2012.
23. S.J. Chadban, E.M. Briganti, and P.G. Kerr et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study J Am Soc Nephrol 14 7 suppl 2 2003 S131 S138
24. H.A. Fink, A. Ishani, and B.C. Taylor et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians clinical practice guideline Ann Intern Med 156 8 2012 570 581
25. N. Freemantle Dealing with uncertainty: will science solve the problems of resource allocation in the U.K. NHS? Soc Sci Med 40 10 1995 1365 1370
26. B. Sibbald, and M. Roland Understanding controlled trials. Why are randomised controlled trials important? BMJ 316 7126 1998 201
27. S. Gao, B.J. Manns, and B.F. Culleton et al. Prevalence of chronic kidney disease and survival among aboriginal people J Am Soc Nephrol 18 11 2007 2953 2959
28. M.E. Tarver-Carr, N.R. Powe, and M.S. Eberhardt et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors J Am Soc Nephrol 13 9 2002 2363 2370
29. C.A. Peralta, M.G. Shlipak, and D. Fan et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease J Am Soc Nephrol 17 10 2006 2892 2899
30. M. Rahman, C.E. Ford, and J.A. Cutler et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR Clin J Am Soc Nephrol 7 6 2012 989 1002
31. F.W. Asselbergs, G.F. Diercks, and H.L. Hillege et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 18 2004 2809 2816
32. K. Omae, T. Ogawa, and K. Nitta Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease Heart Vessels 25 3 2010 203 208
33. The World Bank. GDP per capita. Updated 2012. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed December 20, 2012.
34. I.H. de Boer, T.C. Rue, and P.A. Cleary et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort Arch Intern Med 171 5 2011 412 420
35. K. Matsushita, B.K. Mahmoodi, and M. Woodward et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate JAMA 307 18 2012 1941 1951
36. C.A. Peralta, M.G. Shlipak, and S. Judd et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality JAMA 305 15 2011 1545 1552